Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses
L Zhong, B Li, CS Mah… - Proceedings of the …, 2008 - National Acad Sciences
Recombinant adeno-associated virus 2 (AAV2) vectors are in use in several Phase I/II
clinical trials, but relatively large vector doses are needed to achieve therapeutic benefits …
clinical trials, but relatively large vector doses are needed to achieve therapeutic benefits …
Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses
L Zhong, B Li, CS Mah, L Govindasamy… - Proceedings of the …, 2008 - cir.nii.ac.jp
抄録< jats: p> Recombinant adeno-associated virus 2 (AAV2) vectors are in use in several
Phase I/II clinical trials, but relatively large vector doses are needed to achieve therapeutic …
Phase I/II clinical trials, but relatively large vector doses are needed to achieve therapeutic …
[PDF][PDF] Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses
L Zhong, B Li, CS Mah, L Govindasamy… - PNAS, 2008 - academia.edu
Results Mutations in Surface-Exposed Tyrosine Residues Significantly Improve the
Transduction Efficiency of AAV2 Vectors in HeLa Cells in Vitro. To test our hypothesis that …
Transduction Efficiency of AAV2 Vectors in HeLa Cells in Vitro. To test our hypothesis that …
[HTML][HTML] Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses
L Zhong, B Li, CS Mah, L Govindasamy… - Proceedings of the …, 2008 - ncbi.nlm.nih.gov
Recombinant adeno-associated virus 2 (AAV2) vectors are in use in several Phase I/II
clinical trials, but relatively large vector doses are needed to achieve therapeutic benefits …
clinical trials, but relatively large vector doses are needed to achieve therapeutic benefits …
[PDF][PDF] Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses
L Zhong, B Li, CS Mah, L Govindasamy… - PNAS, 2008 - researchgate.net
Results Mutations in Surface-Exposed Tyrosine Residues Significantly Improve the
Transduction Efficiency of AAV2 Vectors in HeLa Cells in Vitro. To test our hypothesis that …
Transduction Efficiency of AAV2 Vectors in HeLa Cells in Vitro. To test our hypothesis that …
Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses
L Zhong, B Li, CS Mah… - Proceedings of the …, 2008 - pubmed.ncbi.nlm.nih.gov
Recombinant adeno-associated virus 2 (AAV2) vectors are in use in several Phase I/II
clinical trials, but relatively large vector doses are needed to achieve therapeutic benefits …
clinical trials, but relatively large vector doses are needed to achieve therapeutic benefits …
Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses.
L Zhong, B Li, CS Mah, L Govindasamy… - Proceedings of the …, 2008 - europepmc.org
Recombinant adeno-associated virus 2 (AAV2) vectors are in use in several Phase I/II
clinical trials, but relatively large vector doses are needed to achieve therapeutic benefits …
clinical trials, but relatively large vector doses are needed to achieve therapeutic benefits …
Next Generation of Adeno-Associated Virus 2 Vectors: Point Mutations in Tyrosines Lead to High-Efficiency Transduction at Lower Doses
L Zhong, B Li, CS Mah, L Govindasamy… - Proceedings of the …, 2008 - JSTOR
Recombinant adeno-associated virus 2 (AAV2) vectors are in use in several Phase I/II
clinical trials, but relatively large vector doses are needed to achieve therapeutic benefits …
clinical trials, but relatively large vector doses are needed to achieve therapeutic benefits …
Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses
L Zhong, B Li, CS Mah… - Proceedings of the …, 2008 - ui.adsabs.harvard.edu
Recombinant adeno-associated virus 2 (AAV2) vectors are in use in several Phase I/II
clinical trials, but relatively large vector doses are needed to achieve therapeutic benefits …
clinical trials, but relatively large vector doses are needed to achieve therapeutic benefits …
[引用][C] Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses
L ZHONG - Proc Natl Acad Sci USA, 2008 - cir.nii.ac.jp
Next generation of adeno-associated virus 2 vectors : point mutations in tyrosines lead to
high-efficiency transduction at lower doses | CiNii Research CiNii 国立情報学研究所 学術情報 …
high-efficiency transduction at lower doses | CiNii Research CiNii 国立情報学研究所 学術情報 …